Int'l : +1-503-894-6022 | Toll Free : +1-800-792-5285 | help@alliedmarketresearch.com
A00214 | Pages: 229 | Charts: 43 | Tables: 94 |
The global c-reactive protein testing market size was valued at $2,765.07 million in 2020, and is estimated to reach $3,568.69 million by 2030, growing at a CAGR of 2.4% from 2021 to 2030. C-reactive protein (CRP) is an acute-phase protein produced by liver, whose concentrations in the blood rises in response to inflammatory disorders. The c-reactive protein (CRP) test determines the amount of CRP in the blood plasma.
Inflammation is the body's response to an injury or infection by protecting tissues. Autoimmune disorders and chronic diseases such as diabetes, cardiovascular diseases, endometriosis, cancer, and rheumatoid arthritis can cause inflammation. CRP protein has the ability to multiply 1,000-fold in areas of infection or inflammation. The test is used to diagnose infections as well as other medical conditions. The test does not identify direct cause of inflammation, but the degree of inflammation caused by other factors. It is an accurate early warning sign of inflammation or an injury.
Get more information on this report : Request Sample Pages
Growing geriatric population worldwide, as well as escalating demand for healthcare services is expected to drive the market growth. Ageing population is associated with an increase in prevalence of chronic diseases, which is expected lead to an increase in number of tests. Furthermore, sedentary lifestyles and lowered immunity drives CRP testing in healthcare facilities. Diagnostic testing uses increases with age and it is expected that the ageing population would increase demand for c-reactive protein testing. Furthermore, older patients are more likely to have comorbidities such as chronic illnesses, osteoarthritis, and heart problems. As a result, the aforementioned factors are expected to fuel growth of the CRP testing market during the forecast period.
One of the major factors driving the market is the rising prevalence of chronic diseases such as the diabetes, cardiovascular, cancer, inflammatory bowel diseases, arthritis in the general population. Early detection of chronic diseases increases the likelihood of successful treatment. As a result, healthcare providers continually emphasize early diagnosis of clinical disorders rather than spending large sums of money on expensive treatments. Furthermore, increase in various initiatives by governments, non-profit organizations, and key players of the market to create awareness for CRP testing’s plays a pivotal role in by spreading the awareness and thus, further boost the c-reactive protein testing market growth.
The global increase in health disorders has resulted in increased investment in the healthcare industry, which has resulted in technological advancements for determining the levels of c-reactive protein for various diseases. In addition, availability of various point of care devices, rapid kits have boosted the market growth. Furthermore, it reduces medical professional’s workloads by eliminating specimen collection and inspection requests to central laboratories. Thus, development of such novel test kits is anticipated to provide numerous opportunities for key players of the market to invest and contribute towards the market growth during the forecast period. However, availability of alternative disease testing methods for diseases with higher accuracy such as the electrocardiogram (ECG), echocardiogram (ultrasound) for screening of cardiac diseases, and similar products for other diseasesis expected to restrain the c-reactive protein testing market growth.
The COVID-19 outbreak is anticipated to have a positive impact on the growth of the global c-reactive protein testing market. A huge number of clinics and hospitals across the globe were restructured to increase hospital capacity for patients diagnosed with COVID-19. The lockdown led to disruption of manufacturing and transportation of healthcare essentials. Furthermore, other factors responsible for the impact on the market include limited availability of medical care, shortage of healthcare staff and rise in burden of COVID-19 related hospitalization.
However, c-reactive protein (CRP) had been identified as an important marker that increases significantly in severe COVID-19 patients. Its concentration decreases as the inflammatory stages end and the patient heals, thus being utilized as a useful marker for monitoring disease severity and lung lesions. Therefore, CRP testing’s increased in the COVID-19 pandemic and led growth of the market significantly.
Furthermore, untapped, emerging markets are expected to offer potential growth opportunities, due to improved healthcare infrastructure, increase in unmet healthcare needs, and rise in R&D activities. In addition, various technological advancements in rapid diagnostic kits is an emerging opportunity for key players to invest in the c-reactive protein testing market.
The global c-reactive protein testing market is segmented into assay type, application, and region. On the basis of assay type, the market is categorized into enzyme-linked immunosorbent assay (ELISA), chemiluminescence immunoassay (CLIA), immunoturbidimetric assay, and others.
[ASSAYTYPEGRAPH]
By application, the market is bifurcated into diabetes, rheumatoid arthritis, cardiovascular disease, inflammatory bowel disease and others. Region wise, the c-reactive protein testing market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, India, Australia, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, Saudi Arabia, South Africa, and rest of LAMEA).
Depending on the assay type, the immunoturbidimetric assay segment dominated the c-reactive protein testing market in 2020, and is expected to continue this trend during the forecast period, owing to its higher sensitivity, and rapid result technology.
[APPLICATIONGRAPH]
By application, the cardiovascular disease segment exhibited the highest growth in 2020, and is expected to continue this trend during the forecast period, owing to surge in cardiovascular diseases globally
North America accounted for a majority of the global c-reactive protein testing market share in 2020, and is anticipated to remain dominant during the forecast period. This is attributed to increase in prevalence of inflammatory diseases, increase in unhealthy lifestyle, development of new solutions for detection, presence of key players, and rise healthcare expenditure in the region. However, Asia-Pacific is anticipated to witness notable growth, owing to rise in chronic diseases, rise in R&D activities and increase in investments in the healthcare sector in the region. Moreover, India and China are expected to grow at high CAGR in Asia-Pacific c-reactive protein testing market.
The key players operating in the global c-reactive protein testing market are Abbott Laboratories, Danaher Corporation (Beckman Coulter Inc.), F. Hoffmann-La Roche AG, Horiba, Ltd., Quest Diagnostics Incorporated, Merck KGAA (Millipore Sigma), Randox Laboratories Limited, Laboratory Corporation of America Holdings, Thermo Fisher Scientific, Inc., and Zoetis Inc. (Abaxis Inc.).
[REGIONGRAPH]
Key Benefits For Stakeholders
Key Market Segments
Key Market Players
CHAPTER 1:INTRODUCTION
1.1.Report description
1.2.Key benefits for stakeholders
1.3.Key market segments
1.3.1.List of key players profile in the report
1.4.Research methodology
1.4.1.Secondary research
1.4.2.Primary research
1.4.3.Analyst tools and models
CHAPTER 2:EXECUTIVE SUMMARY
2.1.Key findings of the study
2.2.CXO perspective
CHAPTER 3:MARKET LANDSCAPE
3.1.Market definition and scope
3.2.Key findings
3.2.1.Top investment pockets
3.3.Porter’s five forces analysis
3.4.Top player positioning, 2020
3.5.Market dynamics
3.5.1.Drivers
3.5.1.1.Escalating demand for healthcare services from an aging population
3.5.1.2.Rise in prevalence of chronic diseases
3.5.1.3.Technological advancements in the field of c-reactive protein testing
3.5.2.Restraint
3.5.2.1.Availability of alternative disease testing methods
3.5.3.Opportunity
3.5.3.1.Growth in adoption of point-of-care tests
3.6.Impact analysis
3.7.Impact analysis of COVID-19 on the c-reactive protein testing market
CHAPTER 4:C-REACTIVE PROTEIN TESTING MARKET, BY ASSAY TYPE
4.1.Overview
4.1.1.Market size and forecast
4.2.Enzyme-linked immunosorbent assay (ELISA)
4.2.1.Key market trends, growth factors, and opportunities
4.2.2.Market size and forecast, by region
4.2.3.Market analysis, by country
4.3.Chemiluminescence immunoassay (CLIA)
4.3.1.Key market trends, growth factors, and opportunities
4.3.2.Market size and forecast, by region
4.3.3.Market analysis, by country
4.4.Immunoturbidimetric assays
4.4.1.Key market trends, growth factors, and opportunities
4.4.2.Market size and forecast, by region
4.4.3.Market analysis, by country
4.5.Others
4.5.1.Key market trends, growth factors, and opportunities
4.5.2.Market size and forecast, by region
4.5.3.Market analysis, by country
CHAPTER 5:C-REACTIVE PROTEIN TESTING MARKET, BY APPLICATION
5.1.Overview
5.1.1.Market size and forecast
5.2.Diabetes
5.2.1.Market size and forecast, by region
5.2.2.Market analysis, by country
5.3.Rheumatoid arthritis
5.3.1.Market size and forecast, by region
5.3.2.Market analysis, by country
5.4.Cardiovascular diseases
5.4.1.Market size and forecast, by region
5.4.2.Market analysis, by country
5.5.Inflammatory bowel disease
5.5.1.Market size and forecast, by region
5.5.2.Market analysis, by country
5.6.Others
5.6.1.Market size and forecast, by region
5.6.2.Market analysis, by country
CHAPTER 6:C-REACTIVE PROTEIN TESTING MARKET, BY REGION
6.1.Overview
6.1.1.Market size and forecast
6.2.North America
6.2.1.Key market trends, growth factors, and opportunities
6.2.2.North America c-reactive protein testing market, by assay type
6.2.3.North America c-reactive protein testing market, by application
6.2.4.Market size and forecast, by country
6.2.4.1.U.S.
6.2.4.1.1.U.S. c-reactive protein testing market, by assay type
6.2.4.1.2.U.S. c-reactive protein testing market, by application
6.2.4.2.Canada
6.2.4.2.1.Canada c-reactive protein testing market, by assay type
6.2.4.2.2.Canada c-reactive protein testing market, by application
6.2.4.3.Mexico
6.2.4.3.1.Mexico c-reactive protein testing market, by assay type
6.2.4.3.2.Mexico c-reactive protein testing market, by application
6.3.Europe
6.3.1.Key market trends, growth factors, and opportunities
6.3.2.Europe c-reactive protein testing market, by assay type
6.3.3.Europe c-reactive protein testing market, by application
6.3.4.Market size and forecast, by country
6.3.4.1.Germany
6.3.4.1.1.Germany c-reactive protein testing market, by assay type
6.3.4.1.2.Germany c-reactive protein testing market, by application
6.3.4.2.France
6.3.4.2.1.France c-reactive protein testing market, by assay type
6.3.4.2.2.France c-reactive protein testing market, by application
6.3.4.3.UK
6.3.4.3.1.UK c-reactive protein testing market, by assay type
6.3.4.3.2.UK c-reactive protein testing market, by application
6.3.4.4.Italy
6.3.4.4.1.Italy c-reactive protein testing market, by assay type
6.3.4.4.2.Italy c-reactive protein testing market, by application
6.3.4.5.Spain
6.3.4.5.1.Spain c-reactive protein testing market, by assay type
6.3.4.5.2.Spain c-reactive protein testing market, by application
6.3.4.6.Rest of Europe
6.3.4.6.1.Rest of Europe c-reactive protein testing market, by assay type
6.3.4.6.2.Rest of Europe c-reactive protein testing market, by application
6.4.Asia-Pacific
6.4.1.Key market trends, growth factors, and opportunities
6.4.2.Asia-Pacific c-reactive protein testing market, by assay type
6.4.3.Asia-Pacific c-reactive protein testing market, by application
6.4.4.Market size and forecast, by country
6.4.4.1.Japan
6.4.4.1.1.Japan c-reactive protein testing market, by assay type
6.4.4.1.2.Japan c-reactive protein testing market, by application
6.4.4.2.China
6.4.4.2.1.China c-reactive protein testing market, by assay type
6.4.4.2.2.China c-reactive protein testing market, by application
6.4.4.3.Australia
6.4.4.3.1.Australia c-reactive protein testing market, by assay type
6.4.4.3.2.Australia c-reactive protein testing market, by application
6.4.4.4.India
6.4.4.4.1.India c-reactive protein testing market, by assay type
6.4.4.4.2.India c-reactive protein testing market, by application
6.4.4.5.South Korea
6.4.4.5.1.South Korea c-reactive protein testing market, by assay type
6.4.4.5.2.South Korea c-reactive protein testing market, by application
6.4.4.6.Rest of Asia-Pacific
6.4.4.6.1.Rest of Asia-Pacific c-reactive protein testing market, by assay type
6.4.4.6.2.Rest of Asia-Pacific c-reactive protein testing market, by application
6.5.LAMEA
6.5.1.Key market trends, growth factors, and opportunities
6.5.2.LAMEA c-reactive protein testing market, by assay type
6.5.3.LAMEA c-reactive protein testing market, by application
6.5.4.LAMEA c-reactive protein testing market, by country
6.5.4.1.Brazil
6.5.4.1.1.Brazil c-reactive protein testing market, by assay type
6.5.4.1.2.Brazil c-reactive protein testing market, by application
6.5.4.2.Saudi Arabia
6.5.4.2.1.Saudi Arabia c-reactive protein testing market, by assay type
6.5.4.2.2.Saudi Arabia c-reactive protein testing market, by application
6.5.4.3.South Africa
6.5.4.3.1.South Africa c-reactive protein testing market, by assay type
6.5.4.3.2.South Africa c-reactive protein testing market, by application
6.5.4.4.Rest of LAMEA
6.5.4.4.1.Rest of LAMEA c-reactive protein testing market, by assay type
6.5.4.4.2.Rest of LAMEA c-reactive protein testing market, by application
CHAPTER 7:COMPANY PROFILES
7.1.ABBOTT LABORATORIES
7.1.1.Company overview
7.1.2.Company snapshot
7.1.3.Operating business segments
7.1.4.Product portfolio
7.1.5.Business performance
7.2.DANAHER CORPORATION (BECKMAN COULTER INC.)
7.2.1.Company overview
7.2.2.Company snapshot
7.2.3.Operating business segments
7.2.4.Product portfolio
7.2.5.Business performance
7.3.F. HOFFMANN-LA ROCHE AG
7.3.1.Company overview
7.3.2.Company snapshot
7.3.3.Operating business segments
7.3.4.Product portfolio
7.3.5.Business performance
7.3.6.Key strategic moves and developments
7.4.HORIBA, LTD.
7.4.1.Company overview
7.4.2.Company snapshot
7.4.3.Operating business segments
7.4.4.Product portfolio
7.4.5.Business performance
7.4.6.Key strategic moves and developments
7.5.LABORATORY CORPORATION OF AMERICA HOLDINGS
7.5.1.Company overview
7.5.2.Company snapshot
7.5.3.Operating business segments
7.5.4.Product portfolio
7.5.5.Business performance
7.6.MERCK KGAA (MILLIPORE SIGMA)
7.6.1.Company overview
7.6.2.Company snapshot
7.6.3.Operating business segments
7.6.4.Product portfolio
7.6.5.Business performance
7.7.QUEST DIAGNOSTICS INCORPORATED
7.7.1.Company overview
7.7.2.Company snapshot
7.7.3.Operating business segments
7.7.4.Product portfolio
7.7.5.Business performance
7.8.RANDOX LABORATORIES LIMITED
7.8.1.Company overview
7.8.2.Company snapshot
7.8.3.Operating business segments
7.8.4.Product portfolio
7.9.THERMO FISHER SCIENTIFIC, INC.
7.9.1.Company overview
7.9.2.Company snapshot
7.9.3.Operating business segments
7.9.4.Product portfolio
7.9.5.Business performance
7.10.ZOETIS INC. (ABAXIS INC.)
7.10.1.Company overview
7.10.2.Company snapshot
7.10.3.Operating business segments
7.10.4.Product portfolio
7.10.5.Business performance
LIST OF TABLES
TABLE 01.C-REACTIVE PROTEIN TESTING MARKET, BY ASSAY TYPE, 2020–2030 ($MILLION)
TABLE 02.ENZYME-LINKED IMMUNOSORBENT ASSAY (ELISA) MARKET, BY REGION, 2020-2030 ($MILLION)
TABLE 03.CHEMILUMINESCENCE IMMUNOASSAY (CLIA) MARKET, BY REGION, 2020–2030 ($MILLION)
TABLE 04.IMMUNOTURBIDIMETRIC ASSAYS MARKET, BY REGION, 2020–2030 ($MILLION)
TABLE 05.OTHERS MARKET, BY REGION, 2020–2030 ($MILLION)
TABLE 06.C-REACTIVE PROTEIN TESTING MARKET, BY APPLICATION, 2020–2030 ($MILLION)
TABLE 07.C-REACTIVE PROTEIN TESTING MARKET FOR DIABETES, BY REGION, 2020–2030 ($MILLION)
TABLE 08.C-REACTIVE PROTEIN TESTING MARKET FOR RHEUMATOID ARTHRITIS, BY REGION, 2020–2030($MILLION)
TABLE 09.C-REACTIVE PROTEIN TESTING MARKET FOR CARDIOVASCULAR DISEASE, BY REGION, 2020–2030($MILLION)
TABLE 10.C-REACTIVE PROTEIN TESTING MARKET FOR INFLAMMATORY BOWEL DISEASE, BY REGION, 2020–2030($MILLION)
TABLE 11.C-REACTIVE PROTEIN TESTING MARKET FOR OTHERS, BY REGION, 2020–2030($MILLION)
TABLE 12.C-REACTIVE PROTEIN TESTING MARKET, BY REGION, 2020–2030 ($MILLION)
TABLE 13.NORTH AMERICA C-REACTIVE PROTEIN TESTING MARKET, BY ASSAY TYPE, 2020–2030 ($MILLION)
TABLE 14.NORTH AMERICA C-REACTIVE PROTEIN TESTING MARKET, BY APPLICATION, 2020–2030 ($MILLION)
TABLE 15.NORTH AMERICA C-REACTIVE PROTEIN TESTING MARKET, BY COUNTRY, 2020–2030 ($MILLION)
TABLE 16.U.S. C-REACTIVE PROTEIN TESTING MARKET, BY ASSAY TYPE, 2020–2030 ($MILLION)
TABLE 17.U.S. C-REACTIVE PROTEIN TESTING MARKET, BY APPLICATION, 2020–2030 ($MILLION)
TABLE 18.CANADA C-REACTIVE PROTEIN TESTING MARKET, BY ASSAY TYPE, 2020–2030 ($MILLION)
TABLE 19.CANADA C-REACTIVE PROTEIN TESTING MARKET, BY APPLICATION, 2020–2030 ($MILLION)
TABLE 20.MEXICO C-REACTIVE PROTEIN TESTING MARKET, BY ASSAY TYPE, 2020–2030 ($MILLION)
TABLE 21.MEXICO C-REACTIVE PROTEIN TESTING MARKET, BY APPLICATION, 2020–2030 ($MILLION)
TABLE 22.EUROPE C-REACTIVE PROTEIN TESTING MARKET, BY ASSAY TYPE, 2020–2030 ($MILLION)
TABLE 23.EUROPE C-REACTIVE PROTEIN TESTING MARKET, BY APPLICATION, 2020–2030 ($MILLION)
TABLE 24.EUROPE C-REACTIVE PROTEIN TESTING MARKET, BY COUNTRY, 2020–2030 ($MILLION)
TABLE 25.GERMANY C-REACTIVE PROTEIN TESTING MARKET, BY ASSAY TYPE, 2020–2030 ($MILLION)
TABLE 26.GERMANY C-REACTIVE PROTEIN TESTING MARKET, BY APPLICATION, 2020–2030 ($MILLION)
TABLE 27.FRANCE C-REACTIVE PROTEIN TESTING MARKET, BY ASSAY TYPE, 2020–2030 ($MILLION)
TABLE 28.FRANCE C-REACTIVE PROTEIN TESTING MARKET, BY APPLICATION, 2020–2030 ($MILLION)
TABLE 29.UK C-REACTIVE PROTEIN TESTING MARKET, BY ASSAY TYPE, 2020–2030 ($MILLION)
TABLE 30.UK C-REACTIVE PROTEIN TESTING MARKET, BY APPLICATION, 2020–2030 ($MILLION)
TABLE 31.ITALY C-REACTIVE PROTEIN TESTING MARKET, BY ASSAY TYPE, 2020–2030 ($MILLION)
TABLE 32.ITALY C-REACTIVE PROTEIN TESTING MARKET, BY APPLICATION, 2020–2030 ($MILLION)
TABLE 33.SPAIN C-REACTIVE PROTEIN TESTING MARKET, BY ASSAY TYPE, 2020–2030 ($MILLION)
TABLE 34.SPAIN C-REACTIVE PROTEIN TESTING MARKET, BY APPLICATION, 2020–2030 ($MILLION)
TABLE 35.REST OF EUROPE C-REACTIVE PROTEIN TESTING MARKET, BY ASSAY TYPE, 2020–2030 ($MILLION)
TABLE 36.REST OF EUROPE C-REACTIVE PROTEIN TESTING MARKET, BY APPLICATION, 2020–2030 ($MILLION)
TABLE 37.ASIA-PACIFIC C-REACTIVE PROTEIN TESTING MARKET, BY ASSAY TYPE, 2020–2030 ($MILLION)
TABLE 38.ASIA-PACIFIC C-REACTIVE PROTEIN TESTING MARKET, BY APPLICATION, 2020–2030 ($MILLION)
TABLE 39.ASIA-PACIFIC C-REACTIVE PROTEIN TESTING MARKET, BY COUNTRY, 2020–2030 ($MILLION)
TABLE 40.JAPAN C-REACTIVE PROTEIN TESTING MARKET, BY ASSAY TYPE, 2020–2030 ($MILLION)
TABLE 41.JAPAN C-REACTIVE PROTEIN TESTING MARKET, BY APPLICATION, 2020–2030 ($MILLION)
TABLE 42.CHINA C-REACTIVE PROTEIN TESTING MARKET, BY ASSAY TYPE, 2020–2030 ($MILLION)
TABLE 43.CHINA C-REACTIVE PROTEIN TESTING MARKET, BY APPLICATION, 2020–2030 ($MILLION)
TABLE 44.AUSTRALIA C-REACTIVE PROTEIN TESTING MARKET, BY ASSAY TYPE, 2020–2030 ($MILLION)
TABLE 45.AUSTRALIA C-REACTIVE PROTEIN TESTING MARKET, BY APPLICATION, 2020–2030 ($MILLION)
TABLE 46.INDIA C-REACTIVE PROTEIN TESTING MARKET, BY ASSAY TYPE, 2020–2030 ($MILLION)
TABLE 47.INDIA C-REACTIVE PROTEIN TESTING MARKET, BY APPLICATION, 2020–2030 ($MILLION)
TABLE 48.SOUTH KOREA C-REACTIVE PROTEIN TESTING MARKET, BY ASSAY TYPE, 2020–2030 ($MILLION)
TABLE 49.SOUTH KOREA C-REACTIVE PROTEIN TESTING MARKET, BY APPLICATION, 2020–2030 ($MILLION)
TABLE 50.REST OF ASIA-PACIFIC C-REACTIVE PROTEIN TESTING MARKET, BY ASSAY TYPE, 2020–2030 ($MILLION)
TABLE 51.REST OF ASIA-PACIFIC C-REACTIVE PROTEIN TESTING MARKET, BY APPLICATION, 2020–2030 ($MILLION)
TABLE 52.LAMEA C-REACTIVE PROTEIN TESTING MARKET, BY ASSAY TYPE, 2020–2030 ($MILLION)
TABLE 53.LAMEA C-REACTIVE PROTEIN TESTING MARKET, BY APPLICATION, 2020–2030 ($MILLION)
TABLE 54.LAMEA C-REACTIVE PROTEIN TESTING MARKET, BY COUNTRY, 2020–2030 ($MILLION)
TABLE 55.BRAZIL C-REACTIVE PROTEIN TESTING MARKET, BY ASSAY TYPE, 2020–2030 ($MILLION)
TABLE 56.BRAZIL C-REACTIVE PROTEIN TESTING MARKET, BY APPLICATION, 2020–2030 ($MILLION)
TABLE 57.SAUDI ARABIA C-REACTIVE PROTEIN TESTING MARKET, BY ASSAY TYPE, 2020–2030 ($MILLION)
TABLE 58.SAUDI ARABIA C-REACTIVE PROTEIN TESTING MARKET, BY APPLICATION, 2020–2030 ($MILLION)
TABLE 59.SOUTH AFRICA C-REACTIVE PROTEIN TESTING MARKET, BY ASSAY TYPE, 2020–2030 ($MILLION)
TABLE 60.SOUTH AFRICA C-REACTIVE PROTEIN TESTING MARKET, BY APPLICATION, 2020–2030 ($MILLION)
TABLE 61.REST OF LAMEA C-REACTIVE PROTEIN TESTING MARKET, BY ASSAY TYPE, 2020–2030 ($MILLION)
TABLE 62.SAUDI ARABIA C-REACTIVE PROTEIN TESTING MARKET, BY APPLICATION, 2020–2030 ($MILLION)
TABLE 63.ABBOTT: COMPANY SNAPSHOT
TABLE 64.ABBOTT: OPERATING SEGMENTS
TABLE 65.ABBOTT: PRODUCT PORTFOLIO
TABLE 66.DANAHER: COMPANY SNAPSHOT
TABLE 67.DANAHER: PRODUCT SEGMENTS
TABLE 68.DANAHER: PRODUCT PORTFOLIO
TABLE 69.ROCHE: COMPANY SNAPSHOT
TABLE 70.ROCHE: PRODUCT SEGMENTS
TABLE 71.ROCHE: PRODUCT PORTFOLIO
TABLE 72.ROCHE: KEY DEVELOPMENT
TABLE 73.HORIBA: COMPANY SNAPSHOT
TABLE 74.HORIBA: OPERATING BUSINESS SEGMENTS
TABLE 75.HORIBA: PRODUCT PORTFOLIO
TABLE 76.HORIBA: KEY DEVELOPMENTS
TABLE 77.LABCORP: COMPANY SNAPSHOT
TABLE 78.LABCORP: OPERATING BUSINESS SEGMENTS
TABLE 79.LABCORP: PRODUCT PORTFOLIO
TABLE 80.MERCK: COMPANY SNAPSHOT
TABLE 81.MERCK: OPERATING SEGMENTS
TABLE 82.MERCK: PRODUCT PORTFOLIO
TABLE 83.QUEST: COMPANY SNAPSHOT
TABLE 84.QUEST: OPERATING SEGMENTS
TABLE 85.QUEST: PRODUCT PORTFOLIO
TABLE 86.RANDOX: COMPANY SNAPSHOT
TABLE 87.RANDOX: OPERATING SEGMENTS
TABLE 88.RANDOX: PRODUCT PORTFOLIO
TABLE 89.THERMO FISHER: COMPANY SNAPSHOT
TABLE 90.THERMO FISHER: OPERATING SEGMENTS
TABLE 91.THERMO FISHER: PRODUCT PORTFOLIO
TABLE 92.ZOETIS: COMPANY SNAPSHOT
TABLE 93.ZOETIS: PRODUCT SEGMENT
TABLE 94.ZOETIS: PRODUCT PORTFOLIO
LIST OF FIGURES
FIGURE 01.C-REACTIVE PROTEIN TESTING MARKET SEGMENTATION
FIGURE 02.TOP INVESTMENT POCKETS
FIGURE 03.MODERATE BARGAINING POWER OF SUPPLIERS
FIGURE 04.HIGH BARGAINING POWER OF BUYERS
FIGURE 05.MODERATE THREAT OF SUBSTITUTES
FIGURE 06.HIGH THREAT OF NEW ENTRANTS
FIGURE 07.HIGHINTENSITY OF RIVALRY
FIGURE 08.TOP PLAYER POSITIONING, 2020
FIGURE 09.IMPACT ANALYSIS
FIGURE 10.COMPARATIVE ANALYSIS OF ENZYME-LINKED IMMUNOSORBENT ASSAY (ELISA) MARKET, BY COUNTRY, 2021-2030 (%)
FIGURE 11.COMPARATIVE ANALYSIS OF CHEMILUMINESCENCE IMMUNOASSAY (CLIA) MARKET, BY COUNTRY, 2020–2030 (%)
FIGURE 12.COMPARATIVE ANALYSIS OF IMMUNOTURBIDIMETRIC ASSAYS MARKET, BY COUNTRY, 2020–2030 (%)
FIGURE 13.COMPARATIVE ANALYSIS OF OTHERS MARKET, BY COUNTRY, 2020–2030 (%)
FIGURE 14.COMPARATIVE ANALYSIS OF C-REACTIVE PROTEIN TESTING MARKET FOR DIABETES, BY COUNTRY, 2020–2030 (%)
FIGURE 15.COMPARATIVE ANALYSIS OF C-REACTIVE PROTEIN TESTING MARKET FOR RHEUMATOID ARTHRITIS, BY COUNTRY, 2020–2030 (%)
FIGURE 16.COMPARATIVE ANALYSIS OF C-REACTIVE PROTEIN TESTING MARKET FOR CARDIOVASCULAR DISEASE, BY COUNTRY, 2020–2030 (%)
FIGURE 17.COMPARATIVE ANALYSIS OF C-REACTIVE PROTEIN TESTING MARKET FOR INFLAMMATORY BOWEL DISEASE, BY COUNTRY, 2020–2030 (%)
FIGURE 18.COMPARATIVE ANALYSIS OF C-REACTIVE PROTEIN TESTING MARKET FOR OTHERS, BY COUNTRY, 2020–2030 (%)
FIGURE 19.ABBOTT: NET SALES, 2018–2020 ($MILLION)
FIGURE 20.ABBOTT: REVENUE SHARE, BY SEGMENT, 2020 (%)
FIGURE 21.ABBOTT: REVENUE SHARE, BY REGION, 2020(%)
FIGURE 22.DANAHER: NET SALES, 2018–2020 ($MILLION)
FIGURE 23.DANAHER: REVENUE SHARE, BY SEGMENT, 2020 (%)
FIGURE 24.DANAHER: REVENUE SHARE, BY REGION, 2020(%)
FIGURE 25.ROCHE: NET SALES, 2018–2020 ($MILLION)
FIGURE 26.ROCHE: REVENUE SHARE, BY SEGMENT, 2020 (%)
FIGURE 27.ROCHE: REVENUE SHARE, BY REGION, 2020(%)
FIGURE 28.HORIBA: NET SALES, 2018–2020 ($MILLION)
FIGURE 29.HORIBA: REVENUE SHARE, BY SEGMENT, 2020 (%)
FIGURE 30.HORIBA: REVENUE SHARE, BY REGION, 2020 (%)
FIGURE 31.LABCORP: NET SALES, 2018–2020 ($MILLION)
FIGURE 32.LABCORP: REVENUE SHARE, BY SEGMENT, 2020 (%)
FIGURE 33.MERCK: NET SALES, 2018–2020 ($MILLION)
FIGURE 34.MERCK: REVENUE SHARE, BY SEGMENT, 2020 (%)
FIGURE 35.MERCK: REVENUE SHARE, BY REGION, 2020(%)
FIGURE 36.QUEST: NET SALES, 2018–2020 ($MILLION)
FIGURE 37.QUEST: REVENUE SHARE, BY SEGMENTS, 2020 (%)
FIGURE 38.THERMO FISHER: NET SALES, 2018–2020 ($MILLION)
FIGURE 39.THERMO FISHER: REVENUE SHARE, BY SEGMENT, 2020 (%)
FIGURE 40.THERMO FISHER: REVENUE SHARE, BY REGION, 2020(%)
FIGURE 41.ZOETIS: NET SALES, 2018–2020 ($MILLION)
FIGURE 42.ZOETIS: REVENUE SHARE, BY SEGMENT, 2020(%)
FIGURE 43.ZOETIS: REVENUE SHARE, BY REGION, 2020(%)